Table 1. Comparisons of baseline characteristics of total CVD cases and random subcohort in the sample and reweighted to the total WHI cohort.a
VariablesCrudeReweighted to population
Subcohort (n = 1992)Cases (n = 1821)PCohort (N = 58 324)Cases (N = 2438)P
Age, y67.767.80.1162.767.9<0.0001
Black race, %204 (10.2)186 (10.2)0.964207 (7.2)186 (7.6)0.61
White race, %1622 (81.4)1489 (81.8)0.6549 410 (84.7)2106 (86.4)0.12
Height, cm160.9160.80.78161.5160.90.095
Weight, kg70.072.2<0.000172.072.10.85
BMI, kg/m226.927.9<0.000127.327.80.057
Current smoking, %96 (4.8)161 (8.8)<0.00013310 (5.7)207 (8.5)0.010
Hormone therapy, %
    Current830 (41.7)719 (39.6)0.1227 986 (48.0)977 (40.1)<0.0001
    Past286 (14.4)276 (15.2)0.537,051 (12.1)375 (15.4)0.013
BP, mmHg
    SBP129.7135.5<0.0001126.3135.3<0.0001
    Diastolic BP74.375.8<0.000174.875.70.012
Antihypertensive medication use, %529 (26.6)687 (37.7)<0.000113 091 (22.4)909 (37.3)<0.0001
Total cholesterol, mg/dL230.9228.00.047231.0228.40.17
HDL, mg/dL56.851.1<0.000156.651.1<0.0001
Cholesterol-lowering medication, %178 (8.9)176 (9.7)0.554359 (7.5)236 (9.7)0.037
Statin use, %161 (8.1)134 (7.4)0.303921 (6.7)180 (7.4)0.54
hsCRP, mg/Lb2.33.0<0.00012.43.0<0.0001
Diabetes, %93 (4.7)189 (10.4)<0.00012151 (3.7)238 (9.7)<0.0001
Hb A1c (if diabetic), %7.47.90.0137.57.90.11
Angina, %55 (2.8)83 (4.6)0.0041314 (2.3)112 (4.6)0.0007
Family history of early MI, %352 (17.7)403 (22.1)0.000211 413 (19.6)552 (22.7)0.042
Lp-PLA2 activity, mmol/min/mL184.3191.5<0.0001182.0191.9<0.0001
Lp-PLA2 mass, ng/mL499.2531.2<0.0001488.2533.1<0.0001
  • a Mean or percentage except as noted.

  • b Median. Test is based on natural logs.